Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients

O. A. Catalano, E. Nicolai, B. R. Rosen, A. Luongo, M. Catalano, C. Iannace, A. Guimaraes, M. G. Vangel, U. Mahmood, A. Soricelli, M. Salvatore

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Background:Despite improvements in treatments, metastatic breast cancer remains difficult to cure. Bones constitute the most common site of first-time recurrence, occurring in 40-75% of cases. Therefore, evaluation for possible osseous metastases is crucial. Technetium 99 (99 Tc) bone scintigraphy and fluorodexossyglucose (FDG) positron emission tomography (PET)-computed tomography (PET-CT) are the most commonly used techniques to assess osseous metastasis. PET magnetic resonance (PET-MR) imaging is an innovative technique still under investigation. We compared the capability of PET-MR to that of same-day PET-CT to assess osseous metastases in patients with breast cancer.Methods:One hundred and nine patients with breast cancer, who underwent same-day contrast enhanced (CE)-PET-CT and CE-PET-MR, were evaluated. CE-PET-CT and CE-PET-MR studies were interpreted by consensus by a radiologist and a nuclear medicine physician. Correlations with prior imaging and follow-up studies were used as the reference standard. Binomial confidence intervals and a χ 2 test were used for categorical data, and paired t-test was used for the SUVmax data; a non-informative prior Bayesian approach was used to estimate and compare the specificities.Results:Osseous metastases affected 25 out 109 patients. Metastases were demonstrated by CE-PET-CT in 22 out of 25 patients (88%±7%), and by CE-PET-MR in 25 out of 25 patients (100%). CE-PET-CT revealed 90 osseous metastases and CE-PET-MR revealed 141 osseous metastases (P

Original languageEnglish
Pages (from-to)1452-1460
Number of pages9
JournalBritish Journal of Cancer
Volume112
Issue number9
DOIs
Publication statusPublished - Apr 28 2015

Fingerprint

Positron-Emission Tomography
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Bayes Theorem
Nuclear Medicine
Technetium
Radionuclide Imaging
Magnetic Resonance Imaging
Confidence Intervals
Physicians
Recurrence

Keywords

  • breast cancer
  • osseous metastases
  • PET-CT
  • PET-MR
  • skeletal metastases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. / Catalano, O. A.; Nicolai, E.; Rosen, B. R.; Luongo, A.; Catalano, M.; Iannace, C.; Guimaraes, A.; Vangel, M. G.; Mahmood, U.; Soricelli, A.; Salvatore, M.

In: British Journal of Cancer, Vol. 112, No. 9, 28.04.2015, p. 1452-1460.

Research output: Contribution to journalArticle

Catalano, O. A. ; Nicolai, E. ; Rosen, B. R. ; Luongo, A. ; Catalano, M. ; Iannace, C. ; Guimaraes, A. ; Vangel, M. G. ; Mahmood, U. ; Soricelli, A. ; Salvatore, M. / Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. In: British Journal of Cancer. 2015 ; Vol. 112, No. 9. pp. 1452-1460.
@article{7326d747ac7c4c86a7be5dda8f6895b5,
title = "Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients",
abstract = "Background:Despite improvements in treatments, metastatic breast cancer remains difficult to cure. Bones constitute the most common site of first-time recurrence, occurring in 40-75{\%} of cases. Therefore, evaluation for possible osseous metastases is crucial. Technetium 99 (99 Tc) bone scintigraphy and fluorodexossyglucose (FDG) positron emission tomography (PET)-computed tomography (PET-CT) are the most commonly used techniques to assess osseous metastasis. PET magnetic resonance (PET-MR) imaging is an innovative technique still under investigation. We compared the capability of PET-MR to that of same-day PET-CT to assess osseous metastases in patients with breast cancer.Methods:One hundred and nine patients with breast cancer, who underwent same-day contrast enhanced (CE)-PET-CT and CE-PET-MR, were evaluated. CE-PET-CT and CE-PET-MR studies were interpreted by consensus by a radiologist and a nuclear medicine physician. Correlations with prior imaging and follow-up studies were used as the reference standard. Binomial confidence intervals and a χ 2 test were used for categorical data, and paired t-test was used for the SUVmax data; a non-informative prior Bayesian approach was used to estimate and compare the specificities.Results:Osseous metastases affected 25 out 109 patients. Metastases were demonstrated by CE-PET-CT in 22 out of 25 patients (88{\%}±7{\%}), and by CE-PET-MR in 25 out of 25 patients (100{\%}). CE-PET-CT revealed 90 osseous metastases and CE-PET-MR revealed 141 osseous metastases (P",
keywords = "breast cancer, osseous metastases, PET-CT, PET-MR, skeletal metastases",
author = "Catalano, {O. A.} and E. Nicolai and Rosen, {B. R.} and A. Luongo and M. Catalano and C. Iannace and A. Guimaraes and Vangel, {M. G.} and U. Mahmood and A. Soricelli and M. Salvatore",
year = "2015",
month = "4",
day = "28",
doi = "10.1038/bjc.2015.112",
language = "English",
volume = "112",
pages = "1452--1460",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients

AU - Catalano, O. A.

AU - Nicolai, E.

AU - Rosen, B. R.

AU - Luongo, A.

AU - Catalano, M.

AU - Iannace, C.

AU - Guimaraes, A.

AU - Vangel, M. G.

AU - Mahmood, U.

AU - Soricelli, A.

AU - Salvatore, M.

PY - 2015/4/28

Y1 - 2015/4/28

N2 - Background:Despite improvements in treatments, metastatic breast cancer remains difficult to cure. Bones constitute the most common site of first-time recurrence, occurring in 40-75% of cases. Therefore, evaluation for possible osseous metastases is crucial. Technetium 99 (99 Tc) bone scintigraphy and fluorodexossyglucose (FDG) positron emission tomography (PET)-computed tomography (PET-CT) are the most commonly used techniques to assess osseous metastasis. PET magnetic resonance (PET-MR) imaging is an innovative technique still under investigation. We compared the capability of PET-MR to that of same-day PET-CT to assess osseous metastases in patients with breast cancer.Methods:One hundred and nine patients with breast cancer, who underwent same-day contrast enhanced (CE)-PET-CT and CE-PET-MR, were evaluated. CE-PET-CT and CE-PET-MR studies were interpreted by consensus by a radiologist and a nuclear medicine physician. Correlations with prior imaging and follow-up studies were used as the reference standard. Binomial confidence intervals and a χ 2 test were used for categorical data, and paired t-test was used for the SUVmax data; a non-informative prior Bayesian approach was used to estimate and compare the specificities.Results:Osseous metastases affected 25 out 109 patients. Metastases were demonstrated by CE-PET-CT in 22 out of 25 patients (88%±7%), and by CE-PET-MR in 25 out of 25 patients (100%). CE-PET-CT revealed 90 osseous metastases and CE-PET-MR revealed 141 osseous metastases (P

AB - Background:Despite improvements in treatments, metastatic breast cancer remains difficult to cure. Bones constitute the most common site of first-time recurrence, occurring in 40-75% of cases. Therefore, evaluation for possible osseous metastases is crucial. Technetium 99 (99 Tc) bone scintigraphy and fluorodexossyglucose (FDG) positron emission tomography (PET)-computed tomography (PET-CT) are the most commonly used techniques to assess osseous metastasis. PET magnetic resonance (PET-MR) imaging is an innovative technique still under investigation. We compared the capability of PET-MR to that of same-day PET-CT to assess osseous metastases in patients with breast cancer.Methods:One hundred and nine patients with breast cancer, who underwent same-day contrast enhanced (CE)-PET-CT and CE-PET-MR, were evaluated. CE-PET-CT and CE-PET-MR studies were interpreted by consensus by a radiologist and a nuclear medicine physician. Correlations with prior imaging and follow-up studies were used as the reference standard. Binomial confidence intervals and a χ 2 test were used for categorical data, and paired t-test was used for the SUVmax data; a non-informative prior Bayesian approach was used to estimate and compare the specificities.Results:Osseous metastases affected 25 out 109 patients. Metastases were demonstrated by CE-PET-CT in 22 out of 25 patients (88%±7%), and by CE-PET-MR in 25 out of 25 patients (100%). CE-PET-CT revealed 90 osseous metastases and CE-PET-MR revealed 141 osseous metastases (P

KW - breast cancer

KW - osseous metastases

KW - PET-CT

KW - PET-MR

KW - skeletal metastases

UR - http://www.scopus.com/inward/record.url?scp=84928754662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928754662&partnerID=8YFLogxK

U2 - 10.1038/bjc.2015.112

DO - 10.1038/bjc.2015.112

M3 - Article

VL - 112

SP - 1452

EP - 1460

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -